The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Open accessAbstract
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti-CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J.-L., Buist, N., Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., et al. (2001) · Nature Genetics · doi:10.1038/83707 · Cited by 1,922
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Medawar, P. B. (1948) · PubMed · Cited by 1,109
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“At the present time, it is not clear whether the antitumor effects of anti–CTLA-4 ( α CTLA4) antibodies are due to their blockade of a negative regulatory signal in T effector cells (Teffs) or to their interference with Treg function (11).”
Sedgwick, J. D., Schwender, S., Imrich, H., Dörries, R., Butcher, G. W., & ter Meulen, V (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7438 · Cited by 698
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Ahmadzadeh, M., & Rosenberg, S. A. (2006) · Blood · doi:10.1182/blood-2005-06-2399 · Cited by 632
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Weber, J., Thompson, J. A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 568
Chen, X., Bäumel, M., Männel, D. N., Howard, O. M. Z., & Oppenheim, J. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.154 · Cited by 548
Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
Croft, M. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101243 · Cited by 548
Tregs and rethinking cancer immunotherapy
Curiel, T. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31202 · Cited by 547
Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
Dominguez-Villar, M., Baecher-Allan, C. M., & Hafler, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2389 · Cited by 526
Trafficking of immune cells in the central nervous system
Wilson, E. H., Weninger, W., & Hunter, C. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41911 · Cited by 524
O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 514
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 487
Self-citationPhase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
OX40 costimulation turns off Foxp3+ Tregs
Vu, M. D., Xiao, X., Gao, W., Degauque, N., Chen, M., Kroemer, A., Killeen, N., Ishii, N., & Chang Li, X. (2007) · Blood · doi:10.1182/blood-2007-01-070748 · Cited by 428
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Muldoon, L. L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q. R., Hall, W. A., Hynynen, K., Senter, P. D., Peereboom, D. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9861 · Cited by 417
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
Di Giacomo, A. M., Biagioli, M., & Maio, M. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.007 · Cited by 245
Kjærgaard, J., Tanaka, J., Kim, J. A., Rothchild, K. B., Weinberg, A. D., & Shu, S. (2000) · PubMed · Cited by 197
Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy
Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., & Sherry, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1507 · Cited by 191
Targeting Regulatory T Cells in Cancer
Byrne, W. L., Mills, K. H. G., Lederer, J. A., & O'Sullivan, G. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1156 · Cited by 189
FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease
Kryczek, I., Liu, R., Wang, G., Wu, K., Shu, X., Szeliga, W., Vatan, L., Finlayson, E., Huang, E., Simeone, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3804 · Cited by 179
Houot, R., & Levy, R. (2009) · Blood · doi:10.1182/blood-2008-07-170274 · Cited by 178
Self-citationFeng, T., Cao, A., Weaver, C. T., Elson, C. O., & Cong, Y. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.009 · Cited by 167
Nagar, M., Jacob‐Hirsch, J., Vernitsky, H., Berkun, Y., Ben‐Horin, S., Amariglio, N., Bank, I., Kloog, Y., Rechavi, G., & Goldstein, I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902070 · Cited by 156
The reverse stop-signal model for CTLA4 function
Rudd, C. E. (2008) · Nature reviews. Immunology · doi:10.1038/nri2253 · Cited by 155
Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier
Lampson, L. A. (2011) · mAbs · doi:10.4161/mabs.3.2.14239 · Cited by 152
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., Krieg, A. Μ., & Levy, R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2493 · Cited by 125
Self-citationDifferences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome
Ménétrier‐Caux, C., Gobert, M., & Caux, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1642 · Cited by 111
T-regulatory cell modulation: the future of cancer immunotherapy?
Nizar, S. A., Copier, J. P., Meyer, B., Bodman‐Smith, M. D., Galustian, C., Kumar, D., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605040 · Cited by 107
Zhou, G., Lu, Z., McCadden, J., Levitsky, H. I., & Marson, A. L. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041240 · Cited by 107
Self-citationShoham, T., Rajapaksa, R., Kuo, C.-C., Haimovich, J., & Levy, S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1373-1385.2006 · Cited by 104
Self-citationHamano, R., Huang, J., Yoshimura, T., Oppenheim, J. J., & Chen, X. (2011) · European Journal of Immunology · doi:10.1002/eji.201041205 · Cited by 103
Parsa, A. T., Chakrabarti, I., Hurley, P. T., Chi, J. H., Hall, J. S., Kaiser, M. G., & Bruce, J. N. (2000) · Neurosurgery · doi:10.1097/00006123-200010000-00050 · Cited by 97
Cao, X., Leonard, K., Collins, L. I., Cai, S. F., Mayer, J. C., Payton, J. E., Walter, M. J., Piwnica-Worms, D. R., Schreiber, R. D., & Ley, T. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1145 · Cited by 96
Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 72
Self-citationIL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival
Ruby, C. E., Montler, R. D., Zheng, R., Shu, S., & Weinberg, A. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2140 · Cited by 72
Tzeng, J.-J., Barth, R. F., Orosz, C. G., & James, S. M. (1991) · PubMed · Cited by 66
Firefly Luciferase–Based Dynamic Bioluminescence Imaging
Sun, A. L., Hou, L. C., Prugpichailers, T., Dunkel, J., Kalani, M. A., Chen, X. S., Kalani, M. Y. S., & Tse, V. (2010) · Neurosurgery · doi:10.1227/01.neu.0000367452.37534.b1 · Cited by 33
Self-citationImmunological considerations of modern animal models of malignant primary brain tumors
Sughrue, M. E., Yang, I., Kane, A. J., Rutkowski, M. J., Fang, S., James, C. D., & Parsa, A. T. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-84 · Cited by 28
Volovitz, I., Marmor, Y., Azulay, M., Machlenkin, A., Goldberger, O., Mor, F., Slavin, S., Ram, Z., Cohen, I. R., & Eisenbach, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003946 · Cited by 23
Wolchok, J. D., Thomas, L., Bondarenko, I., O'Day, S. J., Weber, J. S., Garbe, C., Francis, S., Ibrahim, R. A., Hoos, A., & Robert, C. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.lba5 · Cited by 21
Cited by
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Self-citationUsing immunotherapy to boost the abscopal effect
Ngwa, W., Irabor, O. C., Schoenfeld, J. D., Hesser, J., Demaria, S., & Formenti, S. C. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.6 · Cited by 1,260
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,041
Metadata
- Authors
- Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., Luong, R., Rosenblum, M. D., Steinman, L., Levitsky, H. I., Tse, V., & Levy, R.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-11-01
- Volume
- 123
- Issue
- 11
- Pages
- 4980-4980
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1978152737
- Cited by
- 307
- References
- 57
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.